Wedge Capital Management L L P NC lowered its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 31.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,087 shares of the company's stock after selling 17,750 shares during the period. Wedge Capital Management L L P NC owned about 0.08% of Prestige Consumer Healthcare worth $3,360,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at $27,000. CIBC Private Wealth Group LLC boosted its position in Prestige Consumer Healthcare by 48.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new stake in Prestige Consumer Healthcare during the fourth quarter worth about $40,000. McIlrath & Eck LLC increased its holdings in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after buying an additional 154 shares in the last quarter. Finally, Johnson Financial Group Inc. acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $93,000. Institutional investors and hedge funds own 99.95% of the company's stock.
Wall Street Analyst Weigh In
Several research firms have issued reports on PBH. Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research note on Saturday, May 17th. Finally, Oppenheimer lifted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a research report on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.33.
View Our Latest Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Price Performance
NYSE PBH traded down $0.14 on Wednesday, hitting $86.51. 27,440 shares of the company's stock were exchanged, compared to its average volume of 298,316. The stock has a 50-day moving average of $83.56 and a 200-day moving average of $82.54. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of 20.26, a P/E/G ratio of 2.69 and a beta of 0.45. Prestige Consumer Healthcare Inc. has a 52 week low of $63.79 and a 52 week high of $90.04. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The business had revenue of $296.52 million during the quarter, compared to the consensus estimate of $289.36 million. During the same quarter in the prior year, the firm earned $1.02 EPS. The firm's revenue was up 7.0% compared to the same quarter last year. Analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.
About Prestige Consumer Healthcare
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Read More
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
